Dr. Todd Golde is a Professor of Pharmacology and Chemical Biology and Neurology at Emory University. He is the Director of the Emory Center for Neurodegenerative Disease (CND) and associate director of the Emory ADRC. Dr. Golde has made significant contributions to the AD field. His work has provided seminal insights into various aspects of AD pathobiology and therapeutics including the role of Ab42, identification of g-secretase modulators, innate immune activation and targeted immunotherapies. Throughout his career Dr. Golde has emphasized collaborative science and has built and led interdisciplinary teams to address complex questions in neurodegenerative disease.
Jacques P. Tremblay
Université Laval
Canada
Professor Jacques P. Tremblay obtained a PhD in Neurosciences from Univ. of California in San Diego (UCSD) in 1974. He has been working on the development of cell and gene therapies for hereditary diseases since 1987. He has published 322 articles in peer-reviewed journals. He received the Henry Friesen Award from the Royal College of Physicians and Surgeons of Canada. He is currently using the Prime editing technology to correct mutations in the APP, DMD, RYR1, DYSF, MYOC and CFTR genes. He is currently trying to identify the best delivery method (AAVs, EVs, LNPs and VLPs) to deliver the components of the Prime editing technology.
Illana Gozes
Tel Aviv University
Israel
Professor, Tel Aviv University (TAU), formerly Lily and Avraham Gildor Chair and Director of the Adams Super Center for Brain Studies. Currently, Director, Elton Laboratory for Molecular Neuroendocrinology. B.Sc. TAU, Ph.D., Weizmann Institute of Science, postdoc. MIT and Salk Institute. Associate Professor, Weizmann Institute, Fogarty-Scholar-in-Residence, NIH, Humboldt Awardee, Germany. Mentored >80 students. Published ~400 papers (h-index 88 -Google Scholar). Inventor of multiple patents including the investigational drug Davunetide (NAP). Discovered ADNP, essential for brain formation implicated in autism, schizophrenia, Alzheimer’s disease and cancer. NAP is the neuroprotective site of ADNP. Received multiple awards for her scientific work.
Leslie M. Shaw
University of Pennsylvania
USA
Leslie Shaw, PhD, directs the Biomarker Research Laboratory and the Toxicology Laboratory at the University of Pennsylvania Medical Center in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Medical Center. He is co-director of the ADNI Biomarker Core laboratory and has published more than 350 scientific papers and reviews in the peer-reviewed literature. Dr Shaw has extensive experience in the development, validation and implementation of biomarker methods in clinical investigations especially multicenter studies. He leads the bioanalytical and clinical validation of Alzheimer’s disease biochemical biomarkers, using advanced mass spectrometric and immunoassay platforms, for the ADNI study where his focus is on the most relevant CSF and plasma biomarkers for early detection, differential diagnosis, monitoring disease progression, and treatment efficacy in Alzheimer’s disease. He is especially interested in identifying and controlling factors that contribute to biomarker measurement variability. Dr Shaw is working collaboratively with other investigators on statistical strategies for combining biochemical and imaging biomarkers for best detection of Alzheimer’s disease. He is also conducting studies in clinical trials of the effects of new treatments on Alzheimer’s disease biomarkers. Dr Shaw co-leads the Biomarker Core of the PENN ADRC. Most recently, he has overseen the successful validation and use in measurements of the plasma AD biomarkers Aβ42/Aβ40, ptau217, GFAP and NfL in ADNI participants and in participants of the PENN ADRC, both sponsored by the NIA.
